-
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
NCT06587828 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Waltham
-
A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
NCT06681623 ·
Phase: Not specified ·
Ages: 55 Years to 80 Years ·
Sex: All (male and female)
· Massachusetts: Foxborough
-
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
NCT06143514 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: Female
· Massachusetts: Boston
-
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
NCT06433752 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston, Burlington, Norfolk
-
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019 ·
Phase: Phase 3 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Massachusetts: Boston
-
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Massachusetts: Foxborough, Wellesley, Worchester
-
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
NCT06782490 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Massachusetts: Foxborough
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248 ·
Phase: Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Massachusetts: Boston
-
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
NCT05704361 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Massachusetts: Worcester
-
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
NCT06063850 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Massachusetts: Boston
-
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
NCT06665165 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
Assessment of Synaptic Density in MS
NCT04634994 ·
Phase: Early Phase 1 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Massachusetts: Boston
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
NCT04047628 ·
Phase: Phase 3 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Massachusetts: Worcester
-
Care in Multiple Sclerosis (MS)
NCT07011914 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis
NCT06441617 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 22 Years and older ·
Sex: All (male and female)
· Massachusetts: Waltham
-
Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study
NCT06649955 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Massachusetts: Boston
-
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
NCT06136728 ·
Phase: Phase 3 ·
Ages: 25 Years to 75 Years ·
Sex: All (male and female)
· Massachusetts: Boston
-
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281 ·
Phase: Phase 3 ·
Ages: 40 Years to 70 Years ·
Sex: All (male and female)
· Massachusetts: Boston, Burlington, Foxborough
-
Efgartigimod for the Treatment of Acute Optic Neuritis
NCT06453694 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
Genes and Environment in Multiple Sclerosis
NCT01353547 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
Glucose Consumption in MS Using [F-18]FDG-PET
NCT07087106 ·
Phase: Phase 4 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Massachusetts: Boston
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
NCT02486562 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Massachusetts: Waltham
-
Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects
NCT04699747 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Massachusetts: Boston
-
Molecular Imaging of NET Using [C-11]MRB-PET in MS
NCT03207464 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Massachusetts: Boston
-
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
NCT06890923 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Massachusetts: Boston
-
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
NCT05285891 ·
Phase: Phase 4 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Massachusetts: Boston, Worcester
-
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
NCT02649985 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 85 Years ·
Sex: All (male and female)
· Massachusetts: Boston
-
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Massachusetts: Boston
-
Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis
NCT04603196 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
NCT07002034 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Massachusetts: Boston, Worcester
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
NCT05104983 ·
Phase: Phase 2 ·
Ages: 1 Day to 6 Months ·
Sex: All (male and female)
· Massachusetts: Boston
-
Study of COYA 302 for the Treatment of ALS
NCT07161999 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Massachusetts: Boston
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
NCT05877963 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Massachusetts: Boston, Foxborough, North Worcester, Wellesley
-
TSC Biosample Repository and Natural History Database
NCT05676099 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Massachusetts: Boston
-
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
NCT03816345 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
Vascular Mechanisms, Functional Outcomes, & Exercise Among Persons With Multiple Sclerosis With Hypertension
NCT06554340 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston